Dual-Mechanism Estrogen Receptor Inhibitors

Researchers developed dual-mechanism estrogen receptor (ER) inhibitors that caused alternate, noncanonical structural perturbations of the receptor ligand-binding domain to antagonize proliferation in ER-positive breast cancer cells and in allele-specific resistance models.